A vs IQV
Agilent Technologies and IQVIA, both Healthcare
Agilent Technologies is the larger company at $36B against $28B. On trailing earnings IQV is the cheaper of the two at a P/E of 32.3 against 33.6, a gap that is only a bargain if the two are growing at similar rates. Over the past year IQV returned +37% against +34% for A.
| Figure | A | IQV |
|---|---|---|
| Last close | $170 | $260 |
| Market cap | $36B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 33.6 | 32.3 |
| Dividend yield | 0.6% | n/a |
| 1-year return | +34% | +37% |
| 5-year return | +2.4% | +1.7% |
| RyuScoresector-relative, 1–10 | 70/100 | 70/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Agilent Technologies
Revenue of $1.9B in Q3 2026, net income $362M. Its largest reported line is Life Sciences And Diagnostics Markets, 48% of the disclosed total.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.